

Edgar Filing: INTEGRATED BIOPHARMA INC - Form 8-K

INTEGRATED BIOPHARMA INC
Form 8-K
February 17, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 13, 2004

INTEGRATED BIOPHARMA, INC.
(Exact Name of Registrant as Specified in Charter)

| | | |
|---|-----------------------------|--------------------------------------|
| Delaware | 000-28876 | 22-2407475 |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

225 Long Ave., Hillside, New Jersey 07205
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code (973) 926-0816

NOT APPLICABLE
(Former Name or Former Address, if Changed Since Last Report)

ITEM 7. Financial Statements and Exhibits.

(c) Exhibits

| Exhibit Number | Description |
|----------------|--|
| 99.1 | Press Release of Integrated BioPharma, Inc. dated February 13, 2004 reporting results for the quarter ended December 31, 2003. |

ITEM 9. Regulation FD Disclosure.

In accordance with SEC Release No. 33-8216, the following information, required to be furnished under "Item 12. Results of Operations and Financial Condition," is furnished under "Item 9. Regulation FD Disclosure".

On February 13, 2004 the Company issued a press release reporting results for the quarter ended December 31, 2003, the text of which is attached

Edgar Filing: INTEGRATED BIOPHARMA INC - Form 8-K

hereto as Exhibit 99.1 and incorporated herein in its entirety by reference.

The statements in this Current Report on Form 8-K, including the exhibits, contain forward-looking statements and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risk and uncertainties which may affect the Registrant's business prospects, including economic, competitive, governmental, technological and other factors discussed in filings with the Securities and Exchange Commission.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

INTEGRATED BIOPHARMA, INC.

February 17, 2004

By: /s/Eric Friedman

Name: Eric Friedman
Title: Vice President

3

EXHIBIT INDEX

| Exhibit Number | Description |
|----------------|--|
| 99.1 | Press Release of Integrated BioPharma, Inc. dated February 13, 2004 reporting results for the quarter ended December 31, 2003. |

4